Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-12-03T19:26:59.289Z Has data issue: false hasContentIssue false
  • English
  • Français

Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica

Published online by Cambridge University Press:  15 October 2010

C. DEVINE ,
G. P. BRENNAN ,
C. E. LANUSSE ,
L. I. ALVAREZ ,
A. TRUDGETT ,
E. HOEY  and
I. FAIRWEATHER
C. DEVINE
Affiliation:
Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
G. P. BRENNAN
Affiliation:
Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
C. E. LANUSSE
Affiliation:
Laboratorio de Farmacología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Campus Universitario (UNCPBA), 7000 Tandil, Argentina
L. I. ALVAREZ
Affiliation:
Laboratorio de Farmacología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Campus Universitario (UNCPBA), 7000 Tandil, Argentina
A. TRUDGETT
Affiliation:
Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
E. HOEY
Affiliation:
Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
I. FAIRWEATHER*
Affiliation:
Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
*
*Corresponding author: School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland. Tel: +44 28 90972298. Fax: +44 28 90975877. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

A study has been carried out to determine whether the action of triclabendazole (TCBZ) against the liver fluke, Fasciola hepatica is altered by inhibition of the cytochrome P450 (CYP 450)-mediated drug metabolism pathway. The Oberon TCBZ-resistant and Cullompton TCBZ-susceptible fluke isolates were used for these experiments, the basic design of which is given in the paper by Devine et al. (2010a). Piperonyl butoxide (PB) was the CYP P450 inhibitor used. Morphological changes resulting from drug treatment and following metabolic inhibition were assessed by means of transmission electron microscopy. After treatment with either TCBZ or TCBZ.SO on their own, there was greater disruption to the TCBZ-susceptible than TCBZ–resistant isolate. However, co-incubation with PB+TCBZ, but more particularly PB+TCBZ.SO, led to greater changes to the TCBZ-resistant isolate than with each drug on its own, with blebbing of the apical plasma membrane, severe swelling of the basal infolds and their associated mucopolysaccharide masses in the syncytium and flooding in the internal tissues. Golgi complexes were greatly reduced or absent in the tegumental cells and the synthesis and production of secretory bodies were badly disrupted. The mitochondria were swollen throughout the tegumental system and the somatic muscle blocks were disrupted. With the TCBZ-susceptible Cullompton isolate, there was a limited increase in drug action following co-incubation with PB. The results provide evidence that the condition of a TCBZ-resistant fluke can be altered by inhibition of drug metabolism. Moreover, they support the concept that altered drug metabolism contributes to the mechanism of resistance to TCBZ.

Keywords

Fasciola hepaticaliver fluketriclabendazole resistancepiperonyl butoxidetransmission electron microscopy
Type
Research Article
Information
Parasitology , Volume 138 , Issue 2 , February 2011 , pp. 224 - 236
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Alvarez, L. I., Solana, H. D., Mottier, M. L., Virkel, G. L., Fairweather, I. and Lanusse, C. E. (2005). Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology 131, 501–510.Google Scholar
Benchaoui, H. A. and McKellar, Q. A. (1996). Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Journal of Pharmacy and Pharmacology 48, 753–759.Google Scholar
Buchanan, J. F., Fairweather, I., Brennan, G. P., Trudgett, A. and Hoey, E. M. (2003). Surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole (‘Valbazen’). Parasitology 126, 141–153.Google Scholar
Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I. (2009). Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology 136, 183–192.Google Scholar
Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I. (2010 a). Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole. Parasitology 137, 871–880.Google Scholar
Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I. (2010 b). Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology Research 106, 1351–1363.CrossRefGoogle Scholar
Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I. (2010c). Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitology Research 107, 337–353.Google Scholar
Fairweather, I., Anderson, H. R. and Threadgold, L. T. (1986). Fasciola hepatica: tegumental changes induced in vitro by the deacetylated (amine) metabolite of diamphenethide. Experimental Parasitology 62, 336–348.Google Scholar
Fairweather, I., Threadgold, L. T. and Hanna, R. E. B. (1999). Development of Fasciola hepatica in the mammalian host. In Fasciolosis (ed. Dalton, J. P.), pp. 47–111. CAB International, Wallingford, Oxon, UK.Google Scholar
Gottschall, D. W., Theodorides, V. J. and Wang, R. (1990). The metabolism of benzimidazole anthelmintics. Parasitology Today 6, 115–124.Google Scholar
Halferty, L., Brennan, G. P., Trudgett, A., Hoey, L. and Fairweather, I. (2009). The relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Veterinary Parasitology 159, 126–138.Google Scholar
McConville, M., Brennan, G. P., Flanagan, A., Edgar, H. W. J., McCoy, M., Castillo, R., Hernández-Campos, A. and Fairweather, I. (2008). Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Veterinary Parasitology 153, 52–64.Google Scholar
McConville, M., Brennan, G. P., Flanagan, A., Edgar, H. W. J., Castillo, R., Hernández-Campos, A. and Fairweather, I. (2009). Ultrastructural changes to the tegumental system and the gastrodermal cells in adult Fasciola hepatica following in vivo treatment with the experimental fasciolicide, compound alpha. Parasitology 136, 665–680.Google Scholar
McKellar, Q. A., Gokbulut, C., Muzandu, K. and Benchaoui, H. (2002). Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. Drug Metabolism and Disposition 30, 1230–1239.Google Scholar
McKinstry, B. D. (2008). Ultrastructural changes observed in Fasciola hepatica following treatment with nitroxynil and triclabendazole, alone and in combination. Ph.D. Thesis, The Queen's University of Belfast, Northern Ireland.Google Scholar
McKinstry, B., Fairweather, I., Brennan, G. P. and Forbes, A. B. (2003). Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (“Trodax”). Parasitology Research 91, 251–263.Google Scholar
McKinstry, B., Brennan, G. P., Halferty, L., Forbes, A. B. and Fairweather, I. (2007). Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitology Research 101, 929–941.Google Scholar
Meaney, M., Fairweather, I., Brennan, G. P., McDowell, L. S. L. and Forbes, A. B. (2003). Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes. Parasitology Research 91, 238–250.CrossRefGoogle Scholar
Meaney, M., Fairweather, I., Brennan, G. P. and Forbes, A. B. (2004). Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following treatment with clorsulon. Parasitology Research 92, 232–241.Google Scholar
Meaney, M., Allister, J., McKinstry, B., McLaughlin, K., Brennan, G. P., Forbes, A. B. and Fairweather, I. (2006). Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitology Research 99, 609–621.Google Scholar
Meaney, M., Allister, J., McKinstry, B., McLauglin, K., Brennan, G. P., Forbes, A. B. and Fairweather, I. (2007). Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitology Research 100, 1091–1104.Google Scholar
Mottier, L., Virkel, G., Solana, H., Alvarez, L., Salles, J. and Lanusse, C. (2004). Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica. Xenobiotica 34, 1043–1047.Google Scholar
Robinson, M. W., Lawson, J., Trudgett, A., Hoey, E. M. and Fairweather, I. (2004). The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitology Research 92, 205–210.Google Scholar
Rogan, M. T. and Threadgold, L. T. (1984). Fasciola hepatica: tegumental changes as a result of lectin binding. Experimental Parasitology 57, 248–260.Google Scholar
Sanchez, S., Small, J., Jones, D. G. and McKellar, Q. A. (2002). Plasma achiral and chiral pharmacokinetic behavior of intravenous oxfendazole co-administered with piperonyl butoxide in sheep. Journal of Veterinary Pharmacology and Therapeutics 25, 7–13.CrossRefGoogle ScholarPubMed
Sanchez-Bruni, S. F. S., Fusé, L. A., Moreno, L., Saumell, C. A., Álvarez, L. I., Fiel, C., McKellar, Q. A. and Lanusse, C. E. (2005). Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Veterinary Journal 37, 257–262.Google Scholar
Skuce, P. J., Anderson, H. R. and Fairweather, I. (1987). The interaction between the deacetylated (amine) metabolite of diamphenethide (DAMD) and cytochemically demonstrable Na+/K+-ATPase activity in the tegument of Fasciola hepatica. Parasitology Research 74, 161–167.Google Scholar
Skuce, P. J. and Fairweather, I. (1990). The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke Fasciola hepatica. Parasitology Research 76, 241–250.Google Scholar
Stitt, A. W. and Fairweather, I. (1993). Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). Parasitology Research 79, 529–536.Google Scholar
Stitt, A. and Fairweather, I. (1994). The effect of the sulphoxide metabolite of triclabendazole (‘Fasinex’) on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology 108, 555–567.CrossRefGoogle ScholarPubMed
Threadgold, L. T. and Brennan, G. P. (1978). Fasciola hepatica: basal infolds and associated vacuoles of the tegument. Experimental Parasitology 46, 300–316.CrossRefGoogle ScholarPubMed
Velík, J., Baliharová, V., Fink-Gremmels, J., Bull, S., Lamka, J. and Skálová, L. (2004). Benzimidazole drugs and modulation of biotransformation enzymes. Research in Veterinary Science 76, 95–108.Google Scholar
Virkel, G., Lifschitz, A., Sallovitz, J., Ballent, M., Scarcella, S. and Lanusse, C. (2009). Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. Journal of Veterinary Pharmacology and Therapeutics 32, 79–86.CrossRefGoogle ScholarPubMed
Walker, S. M., McKinstry, B., Boray, J. C., Brennan, G. P., Trudgett, A., Hoey, E. M., Fletcher, H. and Fairweather, I. (2004). Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitology Research 94, 427–438.Google Scholar